Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

NCT05528354 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic Stem Cell Transplantation
TP53

Interventions

DRUG: VEN and DEC based conditioning regimen
DRUG: DEC

Sponsor

Zhejiang University